Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9872512 | International Journal of Radiation Oncology*Biology*Physics | 2005 | 7 Pages |
Abstract
Conclusions: Our data suggest that the estimated dose to the ICRU rectal point may be a reasonable surrogate for the DRV2. However, this result may not be applicable to other treatment guidelines and ICRT applicator systems. In contrast, the dose to the ICRU bladder point does not appear to be a reasonable surrogate for the DBV2. Correlation with late complications are needed to define the role of three-dimensional dosimetry in treatment planning.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Christopher E. M.D., Matthew B.S., Gregory M. M.D., Anuja M.D., John Ph.D., Patricia J. M.D.,